BackgroundAbdominoplasty complication rates are among the highest for cosmetic surgery. We sought to create a validated scoring system to predict the likelihood of wound complications after abdominoplasty using a national multi-institutional database.MethodsPatients who underwent abdominoplasty in the American College of Surgeons National Surgical Quality Improvement Program 2007–2019 database were analyzed for surgical site complications, a composite outcome of wound disruption, and surgical site infections. The cohort was randomly divided into a 60% testing and a 40% validation sample. Multivariable logistic regression analysis was performed to identify independent predictors of complications using the testing sample (n = 11,294). The predictors were weighted according to β coefficients to develop an integer-based clinical risk score. This system was validated using receiver operating characteristic analysis of the validation sample (n = 7528).ResultsA total of 18,822 abdominoplasty procedures were identified. The proportion of patients who developed a composite surgical site complication was 6.8%. Independent risk factors for composite surgical site complication included inpatient procedure (P < 0.01), smoking (P < 0.01), American Society of Anesthesiologists class ≥3 (P < 0.01), and body mass index ≥25.0 and ≤18.0 kg/m2 (P < 0.01). African American race was a protective factor against surgical site complications (P < 0.01). The factors were integrated into a scoring system, ranging from −5 to 42, and the receiver operating characteristic analysis revealed an area under the curve of 0.71.ConclusionsWe present a validated scoring system for postoperative 30-day surgical site morbidity after abdominoplasty. This system will enable surgeons to optimize patient selection to decrease morbidity and unnecessary healthcare expenditure.
Background: COPD, chronic bronchitis (CB) and active smoking have all been associated with large airway goblet cell hyperplasia (GCH) in small studies. Active smoking is strongly associated with CB, but there is a disconnect between CB clinical symptoms and pathology. Chronic cough and sputum production poorly correlate with the presence of GCH or COPD. We hypothesized that the primary determinant of GCH in ever smokers with or without airflow obstruction is active smoking. Methods: Goblet Cell Density (GCD) was measured in 71 current or former smokers [32 subjects without COPD and 39 COPD subjects] in which endobronchial mucosal biopsies were obtained during the SPIROMICS bronchoscopy substudy. Biopsies were stained with Periodic Acid Schiff-Alcian Blue, and GCD was measured as number of goblet cells/mm basement membrane by two independent observers in a blinded fashion. GCD was divided into tertiles (1=low, 2=medium, 3=high) based on log10 transformed values. Multivariable logistic and linear regressions were performed with CB and current smoking as the independent variables of interest and demographics and FEV1% predicted smoking as covariates.Results: Log10 GCD was greater in current smokers compared to former smokers (1.16±0.28 [n=31] vs. 0.85±0.42 [n=40], p=0.001). Those with classically defined CB had a greater log10 GCD compared to those without CB (1.21±0.31 [n=13] vs. 0.94±0.39 [n=58], p=0.024). Similarly, those with CB by the SGRQ definition had a greater log10 GCD compared to those without CB (1.13±0.39 [n=25] vs. 0.91±0.39 [n=43], p=0.028). Tertiles 2 and 3 had a greater percent of current smokers compared to tertile 1 (16.7, 50.0 and 63.6% in tertiles 1, 2 and 3, respectively, p=0.004). Current smoking was independently associated with tertile 3 (high GCD) (OR 4.15, 95% CI 1.17, 14.71) whereas CB was not in multivariable logistic regression. Similar results were found with multivariable linear regression for log10 GCD.Conclusions: GCD is higher in current smokers with and without airflow obstruction and in CB. However, current smoking, but not CB, is independently associated with GCD. These results suggest that GCH is induced by active smoke exposure and does not necessarily correlate with the clinical symptoms of CB.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.